Type_inhibitor Report for: BACE1-inhibitor

The main neuropathological feature of Alzhzimer's disease consist in extracellular amyloid-beta (A/beta) plaque deposition. The critical molecular event in the AD is the accumulation of Abet neurotoxic oligomers. The proteolytic processing of Amyloid Precursor Protein (APP) by beta-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Abeta. BACE1 is not an alpha beta hydrolase but multitarget compounds are studied that inhibit both BACE1 and cholinesterases for example